Associated Genetic Biomarkers
Associated Diseases
Associated Pathways

Overview

Gene Location [1]
11p15.5
Pathway
MAP kinase signaling
Variant Type
Substitution - Missense
Affected Exon Number
1
Gene
HRAS
SIFT Prediction [3]
Deleterious
ClinVar Prediction [3]
Pathogenic

HRAS G13R is present in 0.08% of AACR GENIE cases, with salivary duct carcinoma, bladder urothelial carcinoma, basal cell carcinoma, breast invasive ductal carcinoma, and embryonal rhabdomyosarcoma having the greatest prevalence [4].

Top Disease Cases with HRAS G13R

Significance of HRAS G13R in Diseases

Lung Adenocarcinoma +

Small Cell Lung Carcinoma +

Squamous Cell Lung Carcinoma +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.

Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.

4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

5. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.